Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants

Brain, Behavior, and Immunity

Volumn 65, Issue , 2017, Pages 230-238

  Borsini, Alessandra ^a   Alboni, Silvia ^b   Horowitz, Mark A ^a   Tojo, Luis M ^a   Cannazza, Giuseppe ^b   Su, Kuan Pin ^c   Pariante, Carmine M ^a,d   Zunszain, Patricia A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cytokines; Fish oil; IL 1 beta; Immune; Kynurenine pathway; Neurogenic; PUFA; Sertraline; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; DOCOSAHEXAENOIC ACID; DOUBLECORTIN; ICOSAPENTAENOIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN 2; OMEGA 3 FATTY ACID; QUINOLINIC ACID; SERTRALINE; VENLAFAXINE; CYTOKINE; IL1B PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; CELL CULTURE TECHNIQUE; DEPRESSION; DRUG EFFECTS; HIPPOCAMPUS; INFLAMMATION; MAJOR DEPRESSION; METABOLISM; PHYSIOLOGY; PROCEDURES; STEM CELL;

ANTIDEPRESSIVE AGENTS; CELL CULTURE TECHNIQUES; CYTOKINES; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HIPPOCAMPUS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; KYNURENINE; NEUROGENESIS; STEM CELLS;

EID: 85019900830     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2017.05.006     Document Type: Article

References (81)

1. Boldrini, M., et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 34:11 (2009), 2376–2389.
2. Kempermann, G., Krebs, J., Fabel, K., The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr. Opin. Psychiatry 21:3 (2008), 290–295.
3. Hill, A.S., Sahay, A., Hen, R., Increasing adult hippocampal neurogenesis is sufficient to reduce anxiety and depression-like behaviors. Neuropsychopharmacology 40:10 (2015), 2368–2378.
4. Warner-Schmidt, J.L., Duman, R.S., Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16:3 (2006), 239–249.
5. Sahay, A., Hen, R., Adult hippocampal neurogenesis in depression. Nat. Neurosci. 10:9 (2007), 1110–1115.
6. Malberg, J.E., Blendy, J.A., Antidepressant action: to the nucleus and beyond. Trends Pharmacol. Sci. 26:12 (2005), 631–638.
7. Goshen, I., et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 13:7 (2008), 717–728.
8. Koo, J.W., Duman, R.S., IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U.S.A. 105:2 (2008), 751–756.
9. Kuzumaki, N., et al. Enhanced IL-1beta production in response to the activation of hippocampal glial cells impairs neurogenesis in aged mice. Synapse 64:9 (2010), 721–728.
10. Capuron, L., Miller, A.H., Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 56:11 (2004), 819–824.
11. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71:2 (2009), 171–186.
12. Maes, M., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24:1 (2009), 27–53.
13. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65:9 (2009), 732–741.
14. Mossner, R., et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J. Biol. Psychiatry 8:3 (2007), 141–174.
15. Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27:1 (2006), 24–31.
16. Schiepers, O.J., Wichers, M.C., Maes, M., Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29:2 (2005), 201–217.
17. Yirmiya, R., Goshen, I., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25:2 (2011), 181–213.
18. Schwarcz, R., et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13:7 (2012), 465–477.
19. Fischer, C.W., et al. Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats. Behav. Brain Res. 293 (2015), 166–172.
20. Raison, C.L., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15:4 (2010), 393–403.
21. Erhardt, S., et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38:5 (2013), 743–752.
22. Brundin, L., et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl. Psychiatry, 6(8), 2016, e865.
23. Capuron, L., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 54:9 (2003), 906–914.
24. Guillemin, G.J., et al. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31:4 (2005), 395–404.
25. Meier, T.B., et al. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav. Immun. 53 (2016), 39–48.
26. Savitz, J., et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav. Immun. 46 (2015), 55–59.
27. O'Connor, J.C., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14:5 (2009), 511–522.
28. Dobos, N., et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J. Alzheimers Dis. 28:4 (2012), 905–915.
29. Zwilling, D., et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:6 (2011), 863–874.
30. Heisler, J.M., O'Connor, J.C., Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav. Immun. 50 (2015), 115–124.
31. Parrott, J.M., et al. Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. Transl. Psychiatry, 6(10), 2016, e918.
32. Zunszain, P.A., et al. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37:4 (2012), 939–949.
33. Anacker, C., et al. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol. Psychiatry, 2011.
34. Hannestad, J., DellaGioia, N., Bloch, M., The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:12 (2011), 2452–2459.
35. Su, K.P., et al. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol. Psychiatry 76:7 (2014), 559–566.
36. Su, K.P., Inflammation in psychopathology of depression: clinical, biological, and therapeutic implications. BioMedicine 2:2 (2012), 68–74.
37. Lin, P.Y., et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol. Psychiatry 17:12 (2012), 1161–1163.
38. Lu, D.Y., et al. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 35:11 (2010), 2238–2248.
39. Lin, P.Y., Huang, S.Y., Su, K.P., A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 68:2 (2010), 140–147.
40. Su, K.P., Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a ‘mind-body interface’?. Neurosignals 17:2 (2009), 144–152.
41. Horowitz, M.A., et al. Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells. Int. J. Neuropsychopharmacol., 18(3), 2015.
42. Anacker, C., et al. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol. Psychiatry 16:7 (2011), 738–750.
43. Bustin, S.A., et al. Quantitative real-time RT-PCR–a perspective. J. Mol. Endocrinol. 34:3 (2005), 597–601.
44. Ekdahl, C.T., Kokaia, Z., Lindvall, O., Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158:3 (2009), 1021–1029.
45. Monje, M.L., Toda, H., Palmer, T.D., Inflammatory blockade restores adult hippocampal neurogenesis. Science 302:5651 (2003), 1760–1765.
46. Kaneko, N., et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 31:12 (2006), 2619–2626.
47. Zhang, X., et al. Venlafaxine increases cell proliferation and regulates DISC1, PDE4B and NMDA receptor 2B expression in the hippocampus in chronic mild stress mice. Eur. J. Pharmacol. 755 (2015), 58–65.
48. Qiu, G., et al. Modulation of the suppressive effect of corticosterone on adult rat hippocampal cell proliferation by paroxetine. Neurosci. Bull. 23:3 (2007), 131–136.
49. Daniele, S., et al. Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NF-kappaB, p38 and JNK. Cell. Signal. 27:8 (2015), 1609–1629.
50. Peng, Z.W., et al. Sertraline promotes hippocampus-derived neural stem cells differentiating into neurons but not glia and attenuates LPS-induced cellular damage. Prog. Neuropsychopharmacol. Biol. Psychiatry 36:1 (2012), 183–188.
51. Song, C., Wang, H., Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:3 (2011), 760–768.
52. Dantzer, R., et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36:3 (2011), 426–436.
53. Perez-De La Cruz, V., Carrillo-Mora, P., Santamaria, A., Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int. J. Tryptophan Res. 5 (2012), 1–8.
54. Guillemin, G.J., Quinolinic acid, the inescapable neurotoxin. FEBS J. 279:8 (2012), 1356–1365.
55. Myint, A.M., et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98:1–2 (2007), 143–151.
56. Halaris, A., et al. Does escitalopram reduce neurotoxicity in major depression?. J. Psychiatr. Res. 66–67 (2015), 118–126.
57. Krause, D.L., et al. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients. Inflammopharmacology 20:3 (2012), 169–176.
58. Elgarf, A.S., et al. Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacol. Biochem. Behav. 126 (2014), 152–162.
59. Norden, D.M., et al. Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue. Physiol. Behav. 140 (2015), 230–235.
60. Molteni, R., et al. Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur. Neuropsychopharmacol. 23:11 (2013), 1645–1655.
61. Katakura, M., et al. Omega-3 polyunsaturated Fatty acids enhance neuronal differentiation in cultured rat neural stem cells. Stem Cells Int., 2013, 2013, 490476.
62. Mingam, R., et al. Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice. Eur. J. Neurosci. 28:9 (2008), 1877–1886.
63. Delpech, J.C., et al. Dietary n-3 PUFAs deficiency increases vulnerability to inflammation-induced spatial memory impairment. Neuropsychopharmacology 40:12 (2015), 2774–2787.
64. Labrousse, V.F., et al. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS ONE, 7(5), 2012, e36861.
65. Larrieu, T., et al. Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. Transl. Psychiatry, 4, 2014, e437.
66. Bazinet, R.P., Laye, S., Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 15:12 (2014), 771–785.
67. Orr, S.K., Trepanier, M.O., Bazinet, R.P., n-3 polyunsaturated fatty acids in animal models with neuroinflammation. Prostaglandins Leukot. Essent. Fatty Acids 88:1 (2013), 97–103.
68. Lotrich, F.E., Sears, B., McNamara, R.K., Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relationship with interleukin-6. Brain Behav. Immun. 31 (2013), 48–53.
69. Kiecolt-Glaser, J.K., et al. Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom. Med. 69:3 (2007), 217–224.
70. Freeman, M.P., Rapaport, M.H., Omega-3 fatty acids and depression: from cellular mechanisms to clinical care. J. Clin. Psychiatry 72:2 (2011), 258–259.
71. Mocking, R.J., et al. Biological profiling of prospective antidepressant response in major depressive disorder: associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity. Psychoneuroendocrinology 79 (2017), 84–92.
72. Mocking, R.J., et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl. Psychiatry, 6, 2016, e756.
73. Grosso, G., et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS ONE, 9(5), 2014, e96905.
74. Grenyer, B.F., et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 31:7 (2007), 1393–1396.
75. Silvers, K.M., et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fatty Acids 72:3 (2005), 211–218.
76. Mozaffari-Khosravi, H., et al. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 23:7 (2013), 636–644.
77. Rondanelli, M., et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J. Am. Coll. Nutr. 29:1 (2010), 55–64.
78. Rizzo, A.M., et al. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters. Nutr. J., 11, 2012, 82.
79. Silvers, K.M., et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fatty Acids 72:3 (2005), 211–218.
80. Su, K.P., et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 13:4 (2003), 267–271.
81. Grenyer, B.F., et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 31:7 (2007), 1393–1396.